Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
Andrea Visentin(University of Padua), Mark‐David Levin(Albert Schweitzer Hospital), Odit Gutwein(Assaf Harofeh Medical Center), Christos Demosthenous(G. Papanikolaou General Hospital), Deepesh Lad(Post Graduate Institute of Medical Education and Research), Julio Delgado(Departament de Salut), Yervand Hakobyan, Massimo Gentile(Azienda Ospedaliera di Cosenza), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Rosa Collado(Hospital General Universitario De Valencia), Gomes da Silva Maria(IPO Porto), Jorge Labrador(Hospital Universitario de Burgos), Giovanni Del Poeta(University of Rome Tor Vergata), David Allsup(University of Leeds), Sabina Kersting(Haga Hospital), Lydia Scarfò(IRCCS Ospedale San Raffaele), Darko Antić(University of Belgrade), Sunil Iyengar(Royal Marsden Hospital), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori), José‐Ángel Hernández‐Rivas(Hospital Universitario Infanta Leonor), Michael Doubek(Central European Institute of Technology), Anargyros Kapetanakis(Centre for Research and Technology Hellas), Gilad Itchaki(Meir Medical Center), Mónica Baile(Instituto de Investigación Biomédica de Salamanca), Alicia Enrico(Hospital Italiano La Plata), Mark Catherwood(University of Ulster), Olga Kalashnikova(First Pavlov State Medical University of St. Petersburg), El-Ashwah Shimaa(Mansoura University), Carolina Cuéllar‐García(Hospital Terrassa), Moritz Fürstenau(University of Cologne), Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Arnon P. Kater(Amsterdam University Medical Centers), Eva Gimeno(Hospital Del Mar), Ann Janssens, Maria Rosaria De Paolis(Istituto Nazionale di Fisica Nucleare, Sezione di Lecce), Luca Laurenti(Fondazione Roma), Raúl Córdoba(Hospital Universitario Fundación Jiménez Díaz), Maria Dimou(National and Kapodistrian University of Athens), Martin Andres(University of Bern), Ozren Jakšić(University of Zagreb), Maria Efstathopoulou(Mansoura University), José A. García‐Marco(Hospital Universitario Puerta de Hierro Majadahonda), Tobias Herold(German Cancer Research Center), Elżbieta Kalicińska(The University of Melbourne), Dominique Bron, Yair Herishanu(Tel Aviv University), Myriam Foglietta(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Antonella Capasso(IRCCS Ospedale San Raffaele), Georgios Karakatsoulis(University of Ioannina)
Cited by 0
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907